Please login to the form below

Not currently logged in
Email:
Password:

Aspen Pharmacare

This page shows the latest Aspen Pharmacare news and features for those working in and with pharma, biotech and healthcare.

Sandoz expands into Japan with €400m Aspen deal

Sandoz expands into Japan with €400m Aspen deal

The agreement will see Sandoz acquire the entirety of Aspen Global Incorporated’s (AGI) Japanese business division, which is a wholly owned subsidiary of Aspen Pharmacare Holdings Limited. ... The proceeds Aspen gains from the transaction will be used

Latest news

  • EU starts investigation of Aspen's cancer drug pricing EU starts investigation of Aspen's cancer drug pricing

    Amid reports of price increases of several hundred per cent. Aspen Pharmacare is under investigation by the EU's competition authorities over its pricing of five cancer medicines, amid allegations of ... The five generic medicines - chlorambucil,

  • GSK sells another chunk of South Africa's Aspen GSK sells another chunk of South Africa's Aspen

    Paid $418m for an 18% share in Aspen in 2009. GlaxoSmithKline (GSK) has cashed in part of its holding in South Africa's Aspen Pharmacare, raising cash to help fund the ... We continue to believe in the strategy of Aspen and we remain committed to working

  • Publicis boosts South Africa presence Publicis boosts South Africa presence

    The agency has 80 staff and works with blue-chip clients such as Aspen Pharmacare, Tanqueray Gin and TOTAL.

  • GSK cashes in its stake in Africa's Aspen GSK cashes in its stake in Africa's Aspen

    Sells 28.2 million shares. GlaxoSmithKline (GSK) has agreed to reduce its stake in Aspen Pharmacare but says it will maintain a "close relationship" with the South African company. ... Aspen's shares dipped nearly 4 per cent on news of the divestment.

  • GSK sells Lucozade and Ribena for £1.35bn GSK sells Lucozade and Ribena for £1.35bn

    it offloaded several other products to to Aspen Pharmacare for £164m.

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Deal Watch table for September 2013 Deal Watch table for September 2013

    840. GSK / Aspen Pharmacare. Acquisition of assets. 2. Arixtra and Fraxiparine - anti-thrombotic agents.

  • Pharma deals during September 2013 Pharma deals during September 2013

    GSK also received $700m from the sale of two thrombosis drugs (Arixtra and Fraxiparine), to Aspen Pharmacare, South Africa's largest drug maker. ... This agreement provides Aspen with the opportunity to expand into Russia and the CIS.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....